University Of Glasgow

New data from the FINEARTS-HF trial show that finerenone improved outcomes in patients with HF compared with placebo across the entire midrange and preserved ejection fraction ranges.

Renin-angiotensin system blockade conferred similar mortality benefits for Black vs. non-Black patients with HF, and despite less benefit for hospitalization for Black patients, absolute benefit was comparable, researchers reported.

Excess risk for cardiovascular disease in patients with gout — including heart failure and arrhythmias — is highest among women and those aged younger than 45 years, according to data published in The Lancet Rheumatology.

Guselkumab demonstrates consistent pharmacological effects across both patients naïve to biologics and those with an inadequate response to TNF inhibitors, according data published in Arthritis & Rheumatology.

Adults with obesity receiving tirzepatide lost more than 25% of their body weight and were able to maintain their weight loss for up to 88 weeks, according to data from the SURMOUNT-4 trial.

Initiation of the nonsteroidal mineralocorticoid receptor antagonist eplerenone shows benefit in patients with HF with reduced ejection fraction, regardless of their disease duration, 1 year or more than 5 years, a speaker reported.

Researchers reported a novel risk model for predicting stroke risk in patients with HF with preserved ejection fraction without atrial fibrillation demonstrated “good” discrimination in an analysis of two large, pooled cohorts.

SAN DIEGO — Adults with obesity and type 2 diabetes achieved a 14.7% weight loss at 72 weeks with 15 mg tirzepatide, according to data from the SURMOUNT-2 trial presented at the American Diabetes Association Scientific Sessions.

Ensuring equal opportunity for patients to receive care, and for practitioners to grow in their careers, is at the heart of EULAR’s mission for 2023 and beyond, according to opening remarks at the EULAR 2023 Congress.

In patients with angina with nonobstructive CAD, invasive testing increased the likelihood of an angina endotype diagnosis and improved treatment satisfaction compared with controls, but did not improve angina burden, researchers reported.